Product Benefits:

• Helps manage symptoms of stable angina pectoris in adult patients who are not adequately controlled with or are intolerant to first‑line anti‑anginal therapies.

• Works by shifting myocardial energy metabolism from fatty‑acid oxidation to glucose oxidation via keto‑acyl CoA thiolase inhibition, improving myocardial efficiency and reducing ischemia‑related damage. 

• No significant hemodynamic changes (e.g., rate, pressure) reported, making it a safer add‑on in many patients under supervision. 

• Convenient twice‑daily modified‑release formulation (35 mg MR) supports improved compliance.